Immune suppression in cynomolgus monkeys by XPro9523

References

• Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19:565 - 94; http://dx.doi.org/10.1146/annurev.immunol.19.1.565; PMID: 11244047
   PubMed Web of Science ®Google Scholar
• Lafferty KJ, Prowse SJ, Simeonovic CJ, Warren HS. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu Rev Immunol 1983; 1:143 - 73; http://dx.doi.org/10.1146/annurev.iy.01.040183.001043; PMID: 6443557
   PubMed Web of Science ®Google Scholar
• Lafferty KJ, Woolnough J. The origin and mechanism of the allograft reaction. Immunol Rev 1977; 35:231 - 62; http://dx.doi.org/10.1111/j.1600-065X.1977.tb00241.x; PMID: 330389
   PubMed Web of Science ®Google Scholar
• Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11:852 - 63; http://dx.doi.org/10.1038/nri3108; PMID: 22116087
   PubMed Web of Science ®Google Scholar
• Wing K, Yamaguchi T, Sakaguchi S. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol 2011; 32:428 - 33; http://dx.doi.org/10.1016/j.it.2011.06.002; PMID: 21723783
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174:561 - 9; http://dx.doi.org/10.1084/jem.174.3.561; PMID: 1714933
   PubMed Web of Science ®Google Scholar
• Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 2008; 121:299 - 306, quiz 307-8; http://dx.doi.org/10.1016/j.jaci.2008.01.002; PMID: 18269922
   PubMed Web of Science ®Google Scholar
• Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5:443 - 53; http://dx.doi.org/10.1111/j.1600-6143.2005.00749.x; PMID: 15707398
   PubMed Web of Science ®Google Scholar
• Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 2007; 34:2204 - 10; PMID: 17787038
   PubMed Web of Science ®Google Scholar
• World Health Organization. Recommended International Nonproprietary Names: List 59. WHO Drug Information 2008; 22:41 - 76
   Google Scholar
• Leister KJ, Schaefer EJ, Bates RC, Bramhall EA, Didio DM, Donaldson R, et al. (Bristol-Myers Squibb Company). Compositions and methods for producing a composition. United States Patent and Trademark Office 2009; US 20090252749A1.
   Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715 - 25; http://dx.doi.org/10.1038/nri2155; PMID: 17703228
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28:157 - 9; http://dx.doi.org/10.1038/nbt.1601; PMID: 20081867
   PubMed Web of Science ®Google Scholar
• Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs 2011; 3:422 - 30; http://dx.doi.org/10.4161/mabs.3.5.16983; PMID: 22048693
   PubMed Web of Science ®Google Scholar
• Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1:793 - 801; http://dx.doi.org/10.1016/S1074-7613(94)80021-9; PMID: 7534620
   PubMed Web of Science ®Google Scholar
• Xu Z, Juan V, Ivanov A, Ma Z, Polakoff D, Powers DB, et al. Affinity and cross-reactivity engineering of CTLA4-Ig to modulate T cell costimulation. J Immunol 2012; 189:4470 - 7; http://dx.doi.org/10.4049/jimmunol.1201813; PMID: 23018459
   PubMed Web of Science ®Google Scholar
• Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 2001; 410:604 - 8; http://dx.doi.org/10.1038/35069112; PMID: 11279501
   PubMed Web of Science ®Google Scholar
• Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 2001; 410:608 - 11; http://dx.doi.org/10.1038/35069118; PMID: 11279502
   PubMed Web of Science ®Google Scholar
• Kliwinski C, Kukral D, Postelnek J, Krishnan B, Killar L, Lewin A, et al. Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J Autoimmun 2005; 25:165 - 71; http://dx.doi.org/10.1016/j.jaut.2005.09.020; PMID: 16256307
   PubMed Web of Science ®Google Scholar
• Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 1995; 96:987 - 93; http://dx.doi.org/10.1172/JCI118146; PMID: 7543497
   PubMed Web of Science ®Google Scholar
• Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265:1225 - 7; http://dx.doi.org/10.1126/science.7520604; PMID: 7520604
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169:5171 - 80; PMID: 12391234
   PubMed Web of Science ®Google Scholar
• Levisetti MG, Padrid PA, Szot GL, Mittal N, Meehan SM, Wardrip CL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159:5187 - 91; PMID: 9548454
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. ORENCIA (package insert). Princeton, New Jersey, USA, 2011.
   Google Scholar
• Bristol-Myers Squibb. NULOJIX (package insert). Princeton, New Jersey, USA, 2011.
   Google Scholar
• Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011; 63:2854 - 64; http://dx.doi.org/10.1002/art.30463; PMID: 21618201
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Belatacept (BMS-224818): briefing document for March 2010 meeting (BLA 125288). FDA Cardiovascular and Renal Drugs Advisory Committee, 2010.
   Google Scholar
• Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997; 94:8789 - 94; http://dx.doi.org/10.1073/pnas.94.16.8789; PMID: 9238056
   PubMed Web of Science ®Google Scholar
• Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46:1470 - 9; http://dx.doi.org/10.1002/art.10294; PMID: 12115176
   PubMed Web of Science ®Google Scholar
• Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc 2007; 2:1269 - 75; http://dx.doi.org/10.1038/nprot.2007.173; PMID: 17546023
   PubMed Web of Science ®Google Scholar